Active Filter(s):
Details:
Novateur proposes a simple treatment paradigm using a combination of a leukotriene biosynthesis blocker, Zyflo® controlled release formulation and an inhibitor of the cysteinyl leukotriene 1 receptor, Singulair® to target the hyper-inflammatory response insevere COVID-19.
Lead Product(s): Zileuton,Montelukast Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Zyflo
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020